Overview

Sarilumab Effect on the Pharmacokinetics of Simvastatin

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the effect of a single 200 mg subcutaneous injection of sarilumab on the pharmacokinetics of simvastatin in patients with rheumatoid arthritis Secondary Objective: To describe the safety and efficacy (exploratory) of sarilumab
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Simvastatin